---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-013879"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:14:25.285188+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# MAIA reports OS >2 years for 8 NSCLC patients; 1 at 33 months in 3L

## Summary
- Eight patients treated with ateganosine + cemiplimab in Phase 2 THIO-101 trial had overall survival exceeding 24 months.
- One 3rd-line patient survived 33 months vs. expected 5.8 months; four 2nd-line patients survived >30 months vs. SOC 10.5 months.
- All patients had failed prior checkpoint inhibitor therapy; 5 of 8 patients have ongoing survival follow-up.
- Phase 3 pivotal trial and Part C expansion (up to 48 patients in Asia/Europe) are enrolling.
- Press release references a $50B+ global immunotherapy market as target opportunity.

## SEC filing metadata
- accession: 0001493152-26-013879
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000149315226013879/0001493152-26-013879-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000149315226013879/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-013879
- JSON: https://secwatch.observer/filing/0001493152-26-013879.json
- Plain text: https://secwatch.observer/filing/0001493152-26-013879.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.